UK Dementia Research Institute, The University of Edinburgh, United Kingdom; Center for Discovery Brain Sciences, The University of Edinburgh, United Kingdom; Center for Clinical Brain Sciences, The University of Edinburgh, United Kingdom.
Center for Clinical Brain Sciences, The University of Edinburgh, United Kingdom.
EBioMedicine. 2022 Sep;83:104241. doi: 10.1016/j.ebiom.2022.104241. Epub 2022 Aug 27.
Alzheimer's Disease, the leading cause of dementia, is over-represented in females. The apolipoprotein E (APOE)ε4 allele is the strongest genetic risk factor for late-onset AD and is associated with aberrant cerebrospinal fluid levels (CSF) of total tau (t-tau), phosphorylated tau (p-tau), and amyloid-β (Aβ). There is some evidence that sex may mediate the relationship between APOE status and CSF tau, however, evidence is mixed.
We aimed to examine the interaction between sex, APOE ε4 status, CSF Aβ on t-tau and p-tau in 1599 mid-to-late life individuals without a diagnosis of dementia in the European Prevention of Alzheimer's Dementia (EPAD) longitudinal cohort study.
We found a significant interaction between APOE status, sex, and CSF Aβ on CSF p-tau levels (β = 0·18, p = 0·04). Specifically, there was a stronger association between APOE status and CSF Aβ on CSF p-tau in males compared to females. Further, in females with high Aβ levels (reflecting less cortical deposition), ε4 carriers had significantly elevated p-tau levels relative to non-carriers (W = 39663, p = 0·01). However, there were no significant differences in p-tau between male ε4 carriers and non-carriers with high Aβ (W = 23523, p = 0·64).
An interaction between sex and cerebrospinal fluid Aβ may mediate the relationship between APOE status and CSF p-tau. These data suggest tau accumulation may be independent of Aβ in females, but not males.
Innovative Medicines Initiative, Swedish Research Council, Alzheimer Drug Discovery Foundation, Swedish Alzheimer Foundation, the Swedish state under the agreement between the Swedish government and the County Councils: the ALF-agreement, and the Alzheimer's Association 2021 Zenith Award.
阿尔茨海默病是痴呆症的主要病因,女性患者更为多见。载脂蛋白 E(APOE)ε4 等位基因是导致晚发性阿尔茨海默病的最强遗传风险因素,与脑脊液中总 tau(t-tau)、磷酸化 tau(p-tau)和淀粉样蛋白-β(Aβ)水平异常相关。有证据表明,性别可能调节 APOE 状态与 CSF tau 之间的关系,但证据并不一致。
我们旨在检查性别、APOE ε4 状态、CSF Aβ 对 1599 名无痴呆症诊断的欧洲预防阿尔茨海默病(EPAD)纵向队列研究中个体的 CSF t-tau 和 p-tau 的影响。
我们发现 APOE 状态、性别和 CSF Aβ 对 CSF p-tau 水平之间存在显著的相互作用(β=0·18,p=0·04)。具体而言,APOE 状态与 CSF Aβ 对男性 CSF p-tau 的关联强于女性。此外,在 Aβ 水平较高的女性中(反映皮质沉积较少),ε4 携带者的 p-tau 水平明显高于非携带者(W=39663,p=0·01)。然而,高 Aβ水平的男性 ε4 携带者与非携带者之间的 p-tau 水平没有显著差异(W=23523,p=0·64)。
性别与脑脊液 Aβ 之间的相互作用可能调节 APOE 状态与 CSF p-tau 之间的关系。这些数据表明,在女性中,tau 积累可能与 Aβ 无关,但在男性中则不是。
创新药物倡议、瑞典研究委员会、阿尔茨海默病药物发现基金会、瑞典阿尔茨海默病基金会、瑞典政府与郡议会之间的协议(瑞典政府与郡议会之间的协议):ALF 协议,以及 2021 年阿尔茨海默病协会 Zenith 奖。